CCM

Our small molecule drug candidates, Rho kinase (ROCK) inhibitors,  inhibit a downstream target of Rho. They have the potential to repair a  broken blood brain barrier.  They have been out-licensed to Neurelis for continued development.

ROCK is hyper-activated in endothelial cells in neurovascular disorders, including the disease of  cerebral cavernous malformation (CCM),  also called cavernous angioma, a serious genetic disease where endothelial lesions in the brain become leaky and bleed. There is no treatment for CCM except invasive surgery. ROCK is a target for treatment because the genetic mutation leading to angioma causes ROCK hyper-activation in brain capillary endothelial cells. Treatments effective for CCM also have utility in treating the blood brain defects in other neurovascular disorders, including stroke.

News


Jan 9, 2023: Cerebral Cavernous Malformation Drug licensed to Neurelis now a clinical stage drug. Click here for the full story.
June 20, 2022: BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210 for treatment of spinal cord injury Click here for the full story .
Aug 28 2020: BioAxone Announces License of Cerebral Cavernous Malformation Drug to to Neurelis. Click here for the full story.

Events

Upcoming scientific conferences on spinal cord injury Click here to access site .
Information on cerebral cavernous malformation Click here to access site .

Address

90 Canal Street
4th Floor
Boston, MA 02114

Phone

617-401-3115

© 2024 BioAxone Biosciences. All Rights Reserved. Site by SolDesigns.net